QuiaPEG Pharmaceuticals AB

– Your choice for half-life extension

QuiaPEG Pharmaceuticals AB has developed a proprietary, releasable pegylation technology platform called Uni-Qleaver®, for the development of prodrugs and biobetters with improved pharmacological properties, e.g. extended half-life and increased tolerability. QuiaPEG’s primary business focus is to develop a pipeline of improved and patentable versions of already approved drugs using the Uni-Qleaver®. In addition, QuiaPEG offers licenses to companies who wish to evaluate releasable pegylation for their own drug development projects.

Visit site